Razi Kebriaei, PhD

Assistant Professor

Outcomes and Translational Sciences

Research Areas: The Division of Pharmaceutics & Pharmacology, Infectious Diseases

538 Parks Hall

Professional Interests

Dr. Kebriaei’s research is focused on treatment of multi-drug resistant bacterial infections. Some examples of the diseases associated with these infections include bacteremia, endocarditis, bone and joint infections and implant associated infections.

Her current work is concentrated on both planktonic and biofilm states of bacteria and novel approaches for combating multi-drug resistant infections. She utilizes various classes of antimicrobials with distinct mechanisms of action to discover optimal treatment options for a wide range of infectious diseases. In addition, she designs and operates pharmacokinetic/pharmacodynamic models to simulate humanized doses in vitro. The majority of knowledge achieved from this research is translatable to bedside and leads to better patient outcomes.

Publications

MtlD as a therapeutic target for intestinal and systemic bacterial infections, Journal of Bacteriology. 2025 Jan | journal-article. doi: 10.1128/jb.00480-24.
Development of Novel Bacterial Topoisomerase Inhibitors Assisted by Computational Screening, ACS Medicinal Chemistry Letters. 2024 Jan | journal-article. doi: 10.1021/acsmedchemlett.4c00162.
It takes two to tango: Preserving daptomycin efficacyagainst daptomycin-resistant MRSA using daptomycin-phage co-therapy, Microbiology Spectrum. 2024 Jan | journal-article. doi: 10.1128/spectrum.00679-24.
Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model, Antimicrobial Agents and Chemotherapy. 2024 Jan | journal-article. doi: 10.1128/aac.01388-23.
Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms, Microbiology Spectrum. 2024 Jan | journal-article. doi: 10.1128/spectrum.03212-23.
Ciprofloxacin in combination with bacteriophage cocktails against multi-drug resistant Pseudomonas aeruginosa in ex vivo simulated endocardial vegetation models, Antimicrobial Agents and Chemotherapy. 2023 Jan | journal-article. doi: 10.1128/aac.00728-23.
Clinical Appraisal of Cefiderocol in the Treatment of Non-fermenting Gram-Negative Bacilli, Current Infectious Disease Reports. 2023 Jan | journal-article. doi: 10.1007/s11908-023-00800-0.
Current therapies and challenges for the treatment of Staphylococcus aureus biofilm-related infections, Pharmacotherapy. 2023 Jan | journal-article. doi: 10.1002/phar.2806.
Evaluation of Omadacycline Alone and in Combination with Rifampin against Staphylococcus aureus and Staphylococcus epidermidis in an In Vitro Pharmacokinetic/Pharmacodynamic Biofilm Model, Antimicrobial Agents and Chemotherapy. 2023 Jan | journal-article. doi: 10.1128/aac.01317-22.
Optimization of Phage-Antibiotic Combinations against Staphylococcus aureus Biofilms, Microbiology Spectrum. 2023 Jan | journal-article. doi: 10.1128/spectrum.04918-22.
Phage-Antibiotic Cocktail Rescues Daptomycin and Phage Susceptibility against Daptomycin-Nonsusceptible Enterococcus faecium in a Simulated Endocardial Vegetation Ex Vivo Model, Microbiology Spectrum. 2023 Jan | journal-article. doi: 10.1128/spectrum.00340-23.
Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models, Antimicrobial Agents and Chemotherapy. 2023 Jan | journal-article. doi: 10.1128/AAC.00578-23.
Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin, Infectious Diseases and Therapy. 2023 Jan | journal-article. doi: 10.1007/s40121-023-00875-1.
Translating phage therapy into the clinic: Recent accomplishments but continuing challenges, Plos Biology. 2023 Jan | journal-article. doi: 10.1371/journal.pbio.3002119.
Activity of the Lactate Dehydrogenase Inhibitor Oxamic Acid against the Fermentative Bacterium Streptococcus mitis/oralis: Bactericidal Effects and Prevention of Daptomycin Resistance In Vitro and in an Ex Vivo Model, Antibiotics. 2022 Jan | journal-article. doi: 10.3390/antibiotics11101409.
Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing, Journal of Applied Microbiology. 2022 Jan | journal-article. doi: 10.1111/jam.15647.
Editorial: Antibiotics Special Issue on Pharmacokinetic/Pharmacodynamic Models of Antibiotics, Antibiotics. 2022 Jan | journal-article. doi: 10.3390/antibiotics11111540.
Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro: Bacteriophage- Antibiotic Combination, Microbiology Spectrum. 2022 Jan | journal-article. doi: 10.1128/spectrum.00411-22.
Evaluation of Bacteriophage Cocktails Alone and in Combination with Daptomycin against Daptomycin-Nonsusceptible Enterococcus faecium, Antimicrobial Agents and Chemotherapy. 2022 Jan | journal-article. doi: 10.1128/AAC.01623-21.
Evaluation of Bacteriophage-Antibiotic Combination Therapy for Biofilm-Embedded MDR Enterococcus faecium, Antibiotics. 2022 Jan | journal-article. doi: 10.3390/antibiotics11030392.
Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant Enterococcus faecium with Preserved Phage Susceptibility, Antibiotics. 2022 Jan | journal-article. doi: 10.3390/antibiotics11091175.
Bacteriophage AB-SA01 cocktail in combination with antibiotics against mrsa-visa strain in an in vitro pharmacokinetic/pharmacodynamic model, Antimicrobial Agents and Chemotherapy. 2021 Jan | journal-article. doi: 10.1128/AAC.01863-20.
Biofilm time-kill curves to assess the bactericidal activity of daptomycin combinations against biofilm-producing vancomycin-resistant enterococcus faecium and faecalis, Antibiotics. 2021 Jan | journal-article. doi: 10.3390/antibiotics10080897.
Clinical pharmacology of bacteriophage therapy: A focus on multidrug-resistant Pseudomonas aeruginosa infections, Antibiotics. 2021 Jan | journal-article. doi: 10.3390/antibiotics10050556.
Exebacase in addition to daptomycin against MRSA, Antimicrobial Agents and Chemotherapy. 2021 Jan | journal-article. doi: 10.1128/AAC.00128-21.
Folate functionalized lipid nanoparticles for targeted therapy of methicillin-resistant staphylococcus aureus, Pharmaceutics. 2021 Jan | journal-article. doi: 10.3390/pharmaceutics13111791.
In vitro antibacterial activity of Cefiderocol against multidrug- resistant Acinetobacter baumannii, Antimicrobial Agents and Chemotherapy. 2021 Jan | journal-article. doi: 10.1128/AAC.02646-20.
In vitro synergy of colistin in combination with meropenem or tigecycline against carbapenem-resistant acinetobacter baumannii, Antibiotics. 2021 Jan | journal-article. doi: 10.3390/antibiotics10070880.
Microfluidic protein detection and quantification using droplet morphology, Microfluidics and Nanofluidics. 2021 Jan | journal-article. doi: 10.1007/s10404-021-02443-w.
Bacteriophage Therapeutics: A Primer for Clinicians on Phage-Antibiotic Combinations, Pharmacotherapy. 2020 Jan | journal-article. doi: 10.1002/phar.2358.
Bacteriophage-antibiotic combination strategy: An alternative against methicillin-resistant phenotypes of staphylococcus aureus, Antimicrobial Agents and Chemotherapy. 2020 Jan | journal-article. doi: 10.1128/AAC.00461-20.
Bacteriophage-antibiotic combinations for enterococcus faecium with varying bacteriophage and daptomycin susceptibilities, Antimicrobial Agents and Chemotherapy. 2020 Jan | journal-article. doi: 10.1128/AAC.00993-20.
Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens, Pharmacotherapy. 2020 Jan | journal-article. doi: 10.1002/phar.2476.
Combinations of (lipo)glycopeptides with b-lactams against MRSA: Susceptibility insights, Journal of Antimicrobial Chemotherapy. 2020 Jan | journal-article. doi: 10.1093/jac/dkaa237.
Dalbavancin, vancomycin and daptomycin alone and in combination with cefazolin against resistant phenotypes of Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model, Antibiotics. 2020 Jan | journal-article. doi: 10.3390/antibiotics9100696.
Drop frequency sensor (DFS): A biomolecular detector based on surfactant retardation, 21st International Conference on Miniaturized Systems for Chemistry and Life Sciences Microtas 2017. 2020 Jan | conference-paper. .
Evaluation of Eravacycline: A Novel Fluorocycline, Pharmacotherapy. 2020 Jan | journal-article. doi: 10.1002/phar.2366.
Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model, Antimicrobial Agents and Chemotherapy. 2020 Jan | journal-article. doi: 10.1128/AAC.02074-19.
Mechanistic Insights into the Differential Efficacy of Daptomycin plus β-Lactam Combinations against Daptomycin-Resistant Enterococcus faecium, Journal of Infectious Diseases. 2020 Jan | journal-article. doi: 10.1093/infdis/jiaa319.
Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19, Pharmacotherapy. 2020 Jan | journal-article. doi: 10.1002/phar.2429.
The evolving reduction of vancomycin and daptomycin susceptibility in mrsa—salvaging the gold standards with combination therapy, Antibiotics. 2020 Jan | journal-article. doi: 10.3390/antibiotics9110762.
Dalbavancin alone and in combination with ceftaroline against four different phenotypes of staphylococcus aureus in a simulated pharmacodynamic/pharmacokinetic model, Antimicrobial Agents and Chemotherapy. 2019 Jan | journal-article. doi: 10.1128/AAC.01743-18.
Daptomycin dose-ranging evaluation with single-dose versus multidose ceftriaxone combinations against streptococcus mitis/ oralis in an ex vivo simulated endocarditis vegetation model, Antimicrobial Agents and Chemotherapy. 2019 Jan | journal-article. doi: 10.1128/AAC.00386-19.
Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus, Journal of Antimicrobial Chemotherapy. 2019 Jan | journal-article. doi: 10.1093/jac/dky376.
Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant klebsiella pneumoniae and pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy. 2019 Jan | journal-article. doi: 10.1128/AAC.00779-19.
Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin, Infectious Diseases and Therapy. 2019 Jan | journal-article. doi: 10.1007/s40121-019-0239-0.
Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations, Antimicrobial Agents and Chemotherapy. 2018 Jan | journal-article. doi: 10.1128/AAC.00101-18.
Combination of tedizolid and daptomycin against methicillin-resistant staphylococcus aureus in an in vitro model of simulated endocardial vegetations, Antimicrobial Agents and Chemotherapy. 2018 Jan | journal-article. doi: 10.1128/AAC.00101-18..
Combination of vancomycin and cefazolin lipid nanoparticles for overcoming antibiotic resistance of MRSA, Materials. 2018 Jan | journal-article. doi: 10.3390/ma11071245.
Influence of inoculum effect on the efficacy of daptomycin monotherapy and in combination with -lactams against daptomycin-susceptible enterococcus faecium harboring liasr substitutions, Antimicrobial Agents and Chemotherapy. 2018 Jan | journal-article. doi: 10.1128/AAC.00315-18.
Droplet frequency sensor: A new modality for sensitive, label-free, inline biochemical detection, Transducers 2017 19th International Conference on Solid State Sensors Actuators and Microsystems. 2017 Jan | conference-paper. doi: 10.1109/TRANSDUCERS.2017.7994131.
Label-free inline hplc detector using a drop generator, 18th International Conference on Miniaturized Systems for Chemistry and Life Sciences Microtas 2014. 2014 Jan | conference-paper. .
Autosizing, closed-loop drop generator using morphometric image feedback, 17th International Conference on Miniaturized Systems for Chemistry and Life Sciences Microtas 2013. 2013 Jan | conference-paper. .